Related Experiment Video
Updated: Jan 18, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Defining 'OFF' time in device-aided therapy criteria for Parkinson's disease: gaps and opportunities
Roongroj Bhidayasiri1, Phooi Leng Lean2, K Ray Chaudhuri3
1Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; The Academy of Science, The Royal Society of Thailand, Bangkok, Thailand.
Abstract:
Evaluating individuals with Parkinson's to determine if they have progressed to the advanced stage and may be suitable for transitioning from intermittent oral medications to continuous, device-aided therapy (DAT) involves considering multiple clinical factors. A key parameter in this assessment, and an indicator of a declining response to oral medication, is overall daily OFF time and the occurrence of unpredictable OFF episodes. OFF-periods are, however, complex and experienced differently by individual patients, so assessment of duration alone may not provide an accurate picture of the patient's lived experience and the challenges they face, information which can be helpful in deciding appropriate management. A range of useful screening tools are available to assist clinicians in determining if a patient has advanced disease and may be suitable for DAT, but these do not always capture the aspects of OFF periods that are the most important, or the most bothersome, to patients. To improve recognition, enhance patient-clinician communication, and achieve effective, personalized management of OFF periods, we propose expanding these tools to consider additional dimensions in three specific areas. First, incorporate patient insights into the personal and functional impact, including the severity of OFF periods, effects on daily activities, and the types and timing (daytime or nighttime) of episodes. Second, include specialist advice from clinicians to characterise the nature of these symptoms and determine suitable therapies. Finally, support this with objective information from PD diaries or technology-based monitoring.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Methods of Documentation II: POMR
Drug Therapy
Antianxiety Medications

